VistaGen Therapeutics Inc (VTGN)
Healthcare
Biotechnology
0.24 $
+0.0%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns VistaGen Therapeutics Inc (VTGN)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 87.0% of the shares are freely tradable; institutional investors hold 40.8%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
40.8%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
0.2%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
87.0%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
4.2%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
41Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Orbimed Advisors, LLC | 7.72 | 3,060,000 | +0.0 | 03/31/2026 |
| TCG Crossover Management, LLC | 6.76 | 2,676,580 | +0.0 | 03/31/2026 |
| Vanguard Group Inc | 4.61 | 1,824,738 | +8.1 | 12/31/2025 |
| Vanguard Capital Management, LLC | 3.97 | 1,574,200 | +0.0 | 03/31/2026 |
| StemPoint Capital LP | 3.11 | 1,233,498 | +100.0 | 03/31/2026 |
| ADAR1 Capital Management LLC | 1.90 | 751,141 | +20.5 | 03/31/2026 |
| Acadian Asset Management LLC | 1.49 | 589,663 | +0.0 | 03/31/2026 |
| Ikarian Capital, LLC | 1.31 | 519,077 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 2.93 | 1,160,455 | +0.0 | 04/30/2026 |
| Biotech Growth Ord | 2.04 | 808,700 | +0.0 | 02/28/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.